ArticleEuropean journal of medical research2025
CDH1 reduces endothelial cell permeability by enhancing CDH5 membrane expression under chronic intermittent hypoxia.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Transcriptomic analysis and experimental verification reveal the involvement of PI3K/AKT signaling pathway in high-altitude cognitive dysfunction.Frontiers in physiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Chronic intermittent hypoxia (CIH) is the primary pathophysiological basis of obstructive sleep apnea (OSA). However, a certain degree of CIH may enhance vascular stability and protect the cardiovascular system.This study aimed to explore the protective role of CDH1 proteins, known as E-cadherin, on the vascular endothelium under CIH, thereby reducing vascular injury from a novel perspective. An endothelial cell model exposed to CIH and oxidized low-density lipoprotein (ox-LDL) were developed. Immunofluorescence staining and FITC-dextran for endothelial permeability were applied to indicate that under CIH, CDH1 exerts a protective effect on vascular endothelial cells by reducing their permeability through promoting the expression of CDH5, referred to as VE-cadherin, on the cell membrane. In contrast, the damage to cells caused by ox-LDL has led to a notable decrease in the expression of the CDH1 protein on the cell membrane. Therefore, the CDH1 protein may be a novel target for treating vascular endothelial cell injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.